中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共6条，第1-6条 帮助

条数/页： 排序方式：
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 期刊论文  OAI收割
BLOOD ADVANCES, 2023, 卷号: 7
作者:  Bachy, Emmanuel;  Savage, Kerry J.;  Huang, Huiqiang;  Kwong, Yok-Lam;  Gritti, Giuseppe
  |  收藏  |  浏览/下载：16/0  |  提交时间：2023/11/10
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study. 期刊论文  OAI收割
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:  Bachy, Emmanuel;  Savage, Kerry J.;  Huang, Huiqiang;  Kwong, Yok-Lam;  Gritti, Giuseppe
  |  收藏  |  浏览/下载：11/0  |  提交时间：2022/12/23
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma 期刊论文  OAI收割
BLOOD ADVANCES, 2022, 卷号: 6
作者:  Yang, Haiyan;  Xiang, Bing;  Song, Yuqin;  Zhang, Huilai;  Zhao, Weili
  |  收藏  |  浏览/下载：24/0  |  提交时间：2022/12/23
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文  OAI收割
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
  |  收藏  |  浏览/下载：51/0  |  提交时间：2022/05/05
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. 期刊论文  OAI收割
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
  |  收藏  |  浏览/下载：53/0  |  提交时间：2022/01/10
S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis 期刊论文  OAI收割
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 卷号: 11, 期号: 3, 页码: 697-724
作者:  Zhang, Linqiang;  Zhang, Zhiguo;  Li, Chengbin;  Zhu, Tingting;  Gao, Jing
  |  收藏  |  浏览/下载：44/0  |  提交时间：2021/05/24